Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for macular edema due to CRVO
NCT06416241Phase 4Completed
- Sponsor
- National and Kapodistrian University of Athens
- Start
- Jan 2017
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
A Phase 4 trial of aflibercept in macular edema secondary to central retinal vein occlusion (ME-CRVO), sponsored by National and Kapodistrian University of Athens. Started Jan 2017; status: completed.
02
Drugs
aflibercept
03
Conditions
macular edema secondary to central retinal vein occlusion (ME-CRVO)
Beyond the preview
Go deeper on NCT06416241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06416241.